Archimed
 
 
 
  • About Us
  • Fund
  • Support
  • Return
  • Our Companies
  • left
    • About Us
    • Our Companies
    • Sustainability & Impact
  • Fund
    • Our Investment Strategy
    • Our Investors
    • Our Funds
  • Support
    • Our Value Creation Approach
    • Our Team and Network
  • Return
    • Return to Investors
    • Return to People
    • Return to Society
  • right
    • News
    • JOIN OUR TEAM
    • Investor Portal
    • Contact

NEWS

Our Latest News

ARCHIMED buys Denmark’s DermaPharm A/S, a leading developer and manufacturer of skincare products

Global private equity healthcare specialist ARCHIMED announces the acquisition of DermaPharm A/V. DermaPharm is a leading player in Nordic suncare and a world-renowned skincare contract development & manufacturing organization for third parties.

 

ARCHIMED buys Denmark’s DermaPharm A/S, a leading developer and manufacturer of skincare products

ARCHIMED raises €3.5 billion for MED Platform II, a record for a buyout fund exclusively investing in healthcare industries

 June

 5, 

2023

ARCHIMED’s sale of Polyplus to Sartorius Stedim earns 300x for MED I, an all-time record return for a private equity investment

 April

 13, 

2023

ARCHIMED completes seventh acquisition for NAMSA, the world leader in Medical Device testing services

 March

 27, 

2023

Majority owner ARCHIMED and partners CAPZA and Siparex finance add-on acquisition by European safety testing company – and French market leader – CARSO

 March

 16, 

2023

ARCHIMED buys WiQo, a pioneer in the field of aesthetic medicine

 March

 9, 

2023

ARCHIMED invests in PlasmidFactory, a German gene and cell therapy specialist

 October

 7, 

2022

< 1 … 3 4 5 6 7 … 17 >
368
  • ARCHIMED © 2026
  • Our Eco-Design Approach
  • Legal Notice
  • SFDR Disclosures
  • Contact Us
  • LinkedIn
  • Manage your cookies
  • .
    Go top

    Back to top